论文部分内容阅读
背景:《中国伏立康唑个体化用药指南》是基于GRADE系统制定的个体化用药指南。指南共识专家组和指导委员会分别于2016年7月1日和5日正式举行了推荐意见共识会议和审定会议,与会专家达成共识并批准了27条推荐意见。目的:了解《中国伏立康唑个体化用药指南》推荐意见的科学性和可行性,以进一步修订推荐意见。方法:针对27条推荐意见的赞成程度、表述清楚程度和可行程度,指南制定工作组以纸质问卷的形式开展外审工作,征求一线医务工作者(临床医师、临床药师)和患者代表的意见和建议,根据外审结果,由指南指导委员会对推荐意见进行修订和完善。结果:来自4家医院、7个科室的12名临床医师、8名临床药师、1名患者代表参与了外审工作。对推荐意见的总体赞成程度为80%,总体表述清楚程度为91%,总体可行程度为80%。所有推荐意见赞成程度、表述清楚程度和可行程度均超过30%。此外,共收到86条主观建议。根据外审结果,指南指导委员会重新修订了14条(52%)推荐意见:修改了5条推荐意见的主体内容;修改了9条推荐意见的表述,并将其中2条推荐意见合并为1条。最终指南包含了26条推荐意见。结论:本次外审工作对《中国伏立康唑个体化用药指南》推荐意见的最终形成提供了依据,进一步完善了所有推荐意见的科学性、明晰性和可行性。
Background: The Chinese Voriconazole Individualized Drug Guide is a personalized guideline based on the GRADE system. The consensus group and the steering committee of the guideline formally held consensus meetings and validation meetings of recommended opinions on July 1 and 5, 2016 respectively, and reached consensus and approved 27 recommendations. OBJECTIVE: To understand the scientificity and feasibility of the recommendations of the “Guidelines for Voriconazole Individualized Use in China” to further revise the recommendations. Methods: According to the degree of approval, articulation and feasibility of the 27 recommendations, the guideline development working group conducted the external audit in the form of a paper questionnaire and sought the opinions of first-line medical workers (clinicians, clinical pharmacists) and patient representatives And recommendations, based on the results of the external audit, the steering committee of the guideline to revise and improve the recommendations. Results: 12 clinicians, 8 clinical pharmacists and 1 patient representative from 4 hospitals and 7 departments participated in the external audit. The overall level of approving of the recommendation is 80%, the overall level of expressiveness is 91% and the overall practicability is 80%. All recommendations agree with the degree of proficiency and the degree of expressiveness are more than 30%. In addition, a total of 86 submissions were received. Based on the results of the external audit, the Guide Steering Committee revised 14 recommendations (52%): amended the main content of the five recommendations; revised the formulation of nine recommendations and merged two of the recommendations into one . The final guide contains 26 recommendations. Conclusion: This review provides the basis for the final formation of the recommendation of “Vorconazole for Individualized Use in China”, which further improves the scientificity, clarity and feasibility of all recommended opinions.